ORGO - Organogenesis Holdings Inc Stock Price, Fair Value and News

2.73USD-0.12 (-4.21%)Delayed

Market Summary

USD2.73-0.12

Delayed

-4.21%

ORGO Alerts

Losses in recent quarter

ORGO Stock Price

View Fullscreen

ORGO RSI Chart

ORGO Valuation

Market Cap

361.9M

Price/Earnings (Trailing)

62.24

Price/Sales (Trailing)

0.83

EV/EBITDA

11.76

Price/Free Cashflow

53.16

ORGO Price/Sales (Trailing)

ORGO Profitability

Operating Margin

75.07%

EBT Margin

2.45%

Return on Equity

2.09%

Return on Assets

1.27%

Free Cashflow Yield

1.88%

ORGO Fundamentals

ORGO Revenue

Revenue (TTM)

435.5M

Rev. Growth (Yr)

2.17%

Rev. Growth (Qtr)

10.36%

ORGO Earnings

Earnings (TTM)

5.8M

Earnings Growth (Yr)

29.27%

Earnings Growth (Qtr)

-269.39%

Breaking Down ORGO Revenue

Last 7 days

-9.9%

Last 30 days

-2.1%

Last 90 days

-21.5%

Trailing 12 Months

-11.6%

How does ORGO drawdown profile look like?

ORGO Financial Health

Current Ratio

2.74

ORGO Investor Care

Shares Dilution (1Y)

1.00%

Diluted EPS (TTM)

0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	435.5M	0	0	0
2023	461.4M	457.3M	449.0M	433.1M
2022	461.9M	460.1M	463.2M	450.9M
2021	379.1M	433.4M	446.3M	467.4M
2020	422.4M	426.5M	463.0M	338.3M
2019	215.0M	236.4M	249.9M	417.8M
2018	194.2M	183.7M	183.0M	193.4M
2017	153.7M	168.6M	183.6M	198.5M
2016	0	0	0	138.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Organogenesis Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	freedman lori	sold (taxes)	-5,527	2.8	-1,974	chief admin. and legal officer
Apr 01, 2024	bilbo patrick	sold (taxes)	-6,991	2.8	-2,497	chief operating officer
Apr 01, 2024	gillheeney gary s.	sold (taxes)	-28,316	2.8	-10,113	president and ceo
Apr 01, 2024	grow brian	sold (taxes)	-5,535	2.8	-1,977	chief commercial officer
Apr 01, 2024	montecalvo antonio s.	sold (taxes)	-4,905	2.8	-1,752	vice president, health policy
Mar 28, 2024	bilbo patrick	acquired	179,655	1.18	152,250	chief operating officer
Feb 21, 2024	leibowitz arthur s	acquired	-	-	51,020	-
Feb 21, 2024	korfin michele ilene	acquired	-	-	51,020	-
Feb 21, 2024	giacomin jon l	acquired	-	-	51,020	-
Feb 21, 2024	gillheeney gary s.	acquired	-	-	685,131	president and ceo

Which funds bought or sold ORGO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	-1,600	3,635	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-27,230	20,059	-%
May 16, 2024	JANE STREET GROUP, LLC	added	175	192,500	403,348	-%
May 16, 2024	Virtus Investment Advisers, Inc.	sold off	-100	-87,935	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-23.89	-183,000	205,000	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-15.65	-943,973	1,334,370	-%
May 15, 2024	MARSHALL WACE, LLP	reduced	-98.16	-3,319,690	42,924	-%
May 15, 2024	Point72 (DIFC) Ltd	new	-	13,021	13,021	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-7.23	-1,277,720	2,312,900	-%
May 15, 2024	Divisadero Street Capital Management, LP	new	-	284,000	284,000	0.07%

Are Funds Buying or Selling ORGO?

Are funds buying ORGO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORGO

No. of Funds

ORGO Alerts

Losses in recent quarter

Unveiling Organogenesis Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	morgan stanley	8.7%	11,505,331	SC 13G
Feb 02, 2024	soleus capital master fund, l.p.	6.8%	8,963,000	SC 13G/A
Apr 06, 2023	blackrock inc.	3.4%	4,488,613	SC 13G/A
Feb 14, 2023	soleus capital master fund, l.p.	5.6%	7,363,063	SC 13G/A
Feb 10, 2023	flynn james e	0%	0	SC 13G/A
Feb 03, 2023	blackrock inc.	8.5%	11,103,190	SC 13G/A
Oct 13, 2022	soleus capital master fund, l.p.	5.1%	6,626,063	SC 13G
Feb 11, 2022	flynn james e	6.57%	8,456,876	SC 13G/A
Feb 04, 2022	blackrock inc.	6.4%	8,239,832	SC 13G
Dec 30, 2021	ades alan a.	20.5%	26,375,746	SC 13D/A

Recent SEC filings of Organogenesis Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	3	Insider Trading
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Organogenesis Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Organogenesis Holdings Inc News

Latest updates

Organogenesis Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	10.4%	110	100	109	117	108	116	117	121	97.00	128	114	123	103	107	101	69.00	62.00	232	64.00	65.00	57.00
Cost Of Revenue	3.3%	29.00	28.00	26.00	26.00	27.00	27.00	26.00	27.00	25.00	33.00	26.00	30.00	25.00	26.00	23.00	20.00	19.00	20.00	19.00	19.00	17.00
Gross Profit	13.1%	81.00	72.00	83.00	91.00	81.00	88.00	91.00	95.00	72.00	95.00	88.00	93.00	77.00	81.00	78.00	49.00	43.00	54.00	45.00	46.00	40.00
Operating Expenses	16.4%	85.00	73.00	75.00	81.00	85.00	80.00	89.00	83.00	72.00	76.00	71.00	70.00	64.00	60.00	55.00	51.00	58.00	56.00	53.00	53.00	52.00
S&GA Expenses	17.8%	72.00	61.00	64.00	70.00	74.00	68.00	79.00	73.00	64.00	67.00	62.00	62.00	58.00	54.00	51.00	47.00	53.00	53.00	49.00	49.00	49.00
R&D Expenses	8.8%	13.00	12.00	10.00	11.00	11.00	11.00	10.00	10.00	9.00	8.00	9.00	7.00	6.00	6.00	4.00	5.00	5.00	4.00	4.00	4.00	3.00
EBITDA Margin	0.1%	0.05*	0.05*	0.07*	0.05*	0.06*	0.06*	0.09*	0.11*	0.14*	0.16*	0.17*	0.20*	-	-	-	-	-	-	-	-	-
Interest Expenses	2.3%	1.00	1.00	0.00	1.00	1.00	-0.03	1.00	1.00	1.00	1.00	1.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00
Income Taxes	-82.7%	-2.24	-1.23	4.00	4.00	-1.66	1.00	1.00	2.00	0.00	-32.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Earnings Before Taxes	-141.7%	-4.34	-1.80	8.00	9.00	-4.63	9.00	1.00	11.00	-0.87	19.00	13.00	21.00	10.00	19.00	21.00	-5.14	-16.28	-2.61	-10.69	-9.63	-15.63
EBT Margin	2.2%	0.02*	0.02*	0.05*	0.03*	0.04*	0.04*	0.07*	0.09*	0.11*	0.13*	0.14*	0.16*	-	-	-	-	-	-	-	-	-
Net Income	-269.4%	-2.10	-0.57	3.00	5.00	-2.97	7.00	0.00	9.00	-0.91	51.00	13.00	21.00	10.00	18.00	21.00	-5.17	-16.31	-2.65	-10.74	-9.65	-15.67
Net Income Margin	16.9%	0.01*	0.01*	0.03*	0.02*	0.03*	0.03*	0.13*	0.16*	0.18*	0.20*	0.14*	0.16*	-	-	-	-	-	-	-	-	-
Free Cashflow	-269.9%	-12.38	7.00	11.00	1.00	-12.64	-2.86	-4.95	4.00	-5.26	13.00	11.00	13.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.3%	458	460	463	450	446	449	457	456	436	443	370	356	319	290	246	216	208	221	175	168	176
Current Assets	0.9%	227	225	226	216	217	223	231	232	218	227	212	202	185	174	129	118	111	126	81.00	76.00	85.00
Cash Equivalents	-14.0%	89.00	104	98.00	89.00	89.00	102	108	113	109	115	103	90.00	78.00	85.00	37.00	41.00	47.00	60.00	23.00	20.00	31.00
Inventory	-2.0%	28.00	28.00	28.00	25.00	26.00	25.00	25.00	23.00	23.00	25.00	29.00	28.00	30.00	28.00	30.00	29.00	26.00	23.00	20.00	19.00	18.00
Net PPE	-1.7%	114	116	118	112	107	102	97.00	93.00	84.00	79.00	75.00	70.00	62.00	56.00	56.00	53.00	50.00	47.00	44.00	41.00	39.00
Goodwill	0%	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	3.00	26.00	26.00	26.00	26.00	26.00	26.00
Liabilities	-0.5%	180	181	186	179	182	184	201	202	195	202	181	177	162	148	181	181	168	165	162	145	144
Current Liabilities	2.8%	83.00	81.00	81.00	73.00	76.00	75.00	89.00	88.00	78.00	83.00	81.00	85.00	74.00	68.00	66.00	66.00	55.00	60.00	57.00	50.00	52.00
Shareholder's Equity	-0.2%	278	279	277	271	264	266	256	254	242	241	189	175	153	142	61.00	32.00	40.00	52.00	13.00	23.00	33.00
Retained Earnings	-5.1%	-43.07	-40.97	-40.40	-43.57	-48.88	-45.30	-52.79	-53.00	-61.75	-60.83	-111	-120	-140	-155	-171	-192	-187	-171	-166	-155	-145
Additional Paid-In Capital	0.5%	321	320	317	315	313	311	309	307	303	302	301	299	298	297	237	228	228	227	179	178	178
Shares Outstanding	0.9%	133	131	131	131	131	131	131	130	129	128	128	128	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	236	-	-	-	345	-	-	-	1,100	-	-	-	43.00	-	-	-	48.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-195.8%	-10,162	10,613	16,735	8,646	-5,077	7,800	5,453	10,195	1,411	17,948	27,850	17,480	-1,300	23,215	8,869	-9,335	-17,283	-6,401	-5,453	-12,116	-9,558
Share Based Compensation	1.7%	2,407	2,366	2,417	2,299	1,914	1,855	1,702	1,692	1,303	1,083	1,041	1,042	698	497	486	469	209	236	242	234	224
Cashflow From Investing	33.2%	-2,222	-3,324	-5,979	-7,499	-7,562	-10,656	-10,402	-6,168	-6,672	-5,227	-16,703	-4,333	-4,957	-5,418	-11,962	-1,875	-4,243	-3,458	-1,275	-1,184	-317
Cashflow From Financing	-46.8%	-2,608	-1,777	-1,438	-1,054	-1,236	-1,875	26.00	415	-765	-917	1,270	-798	-591	30,123	-775	4,890	8,230	47,070	9,728	2,796	19,133

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ORGO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 109,976	$ 107,642
Cost of goods sold	28,696	26,607
Gross profit	81,280	81,035
Operating expenses:
Selling, general and administrative	72,322	73,834
Research and development	12,810	11,202
Total operating expenses	85,132	85,036
Loss from operations	(3,852)	(4,001)
Other expense, net:
Interest expense, net	(514)	(649)
Other income, net	23	23
Total other expense, net	(491)	(626)
Net loss before income taxes	(4,343)	(4,627)
Income tax benefit	2,243	1,658
Net loss and comprehensive loss	$ (2,100)	$ (2,969)
Net loss, per share:
Basic	$ (0.02)	$ (0.02)
Diluted	$ (0.02)	$ (0.02)
Weighted-average common shares outstanding
Basic	131,861,772	131,083,841
Diluted	131,861,772	131,083,841

ORGO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 88,626	$ 103,840
Restricted cash	720	498
Accounts receivable, net	96,148	81,999
Inventories, net	27,694	28,253
Prepaid expenses and other current assets	13,979	10,454
Total current assets	227,167	225,044
Property and equipment, net	114,245	116,228
Intangible assets, net	14,970	15,871
Goodwill	28,772	28,772
Operating lease right-of-use assets, net	38,616	40,118
Deferred tax asset, net	28,002	28,002
Other assets	6,709	5,990
Total assets	458,481	460,025
Current liabilities:
Current portion of term loan	5,489	5,486
Current portion of finance lease obligations	1,103	1,081
Current portion of operating lease obligations - related party	8,543	8,413
Current portion of operating lease obligations	4,675	4,731
Accounts payable	23,230	30,724
Accrued expenses and other current liabilities	39,759	30,074
Total current liabilities	82,799	80,509
Term loan, net of current portion	59,371	60,745
Finance lease obligations, net of current portion	1,604	1,888
Operating lease obligations, net of current portion - related party	11,052	11,954
Operating lease obligations, net of current portion	24,383	25,053
Other liabilities	1,242	1,213
Total liabilities	180,451	181,362
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued
Common stock, $0.0001 par value; 400,000,000 shares authorized; 133,267,888 and 132,044,944 shares issued; 132,539,340 and 131,316,396 shares outstanding at March 31, 2024 and December 31, 2023, respectively.	13	13
Additional paid-in capital	321,088	319,621
Accumulated deficit	(43,071)	(40,971)
Total stockholders' equity	278,030	278,663
Total liabilities and stockholders' equity	$ 458,481	$ 460,025

About Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary wound covering; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly AM, PuraPly XT, and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

CEO	Mr. Gary S. Gillheeney Sr.
WEBSITE	https://organogenesis.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1030

Organogenesis Holdings Inc Frequently Asked Questions

What is the ticker symbol for Organogenesis Holdings Inc? What does ORGO stand for in stocks?

ORGO is the stock ticker symbol of Organogenesis Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Organogenesis Holdings Inc (ORGO)?

As of Fri May 17 2024, market cap of Organogenesis Holdings Inc is 361.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORGO stock?

You can check ORGO's fair value in chart for subscribers.

What is the fair value of ORGO stock?

You can check ORGO's fair value in chart for subscribers. The fair value of Organogenesis Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Organogenesis Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORGO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Organogenesis Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ORGO is over valued or under valued. Whether Organogenesis Holdings Inc is cheap or expensive depends on the assumptions which impact Organogenesis Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORGO.

What is Organogenesis Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ORGO's PE ratio (Price to Earnings) is 62.24 and Price to Sales (PS) ratio is 0.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORGO PE ratio will change depending on the future growth rate expectations of investors.